Plus Therapeutics, Inc.
4200 Marathon Blvd., Suite 200
Austin, TX 78756
June 20, 2024
VIA EDGAR
Mr. Tyler Howes
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
| Re: | Plus Therapeutics, Inc. |
Registration Statement on Form S-1
File No. 333-280061
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned, on behalf of Plus Therapeutics, Inc. (the “Company”), respectfully requests that the effective date of the Registration Statement on Form S-1 referred to above be accelerated so that it will become effective at 5:00 P.M. Eastern Time on June 24, 2024, or as soon as practicable thereafter, or at such other time as the Company may orally request by telephone.
Please contact William Intner of Hogan Lovells US LLP, counsel to the Company, at (410) 659-2778, to provide notice of effectiveness, or if you have any questions or require additional information regarding this matter. Thank you for your assistance and cooperation in this matter.
| Very truly yours,
| ||
| PLUS THERAPEUTICS, INC.
| ||
| By: | /s/ Marc H. Hedrick | |
| March H. Hedrick | ||
| President and Chief Executive Officer | ||
| cc: | Andrew Sims, Plus Therapeutics, Inc. |
Kara Davis, Plus Therapeutics, Inc
William Intner, Hogan Lovells US LLP
Andrew L. Strong, Hogan Lovells US LLP